Longevity
Nicotinamide mononucleotide
NMN
NMN is a nucleotide precursor to nicotinamide adenine dinucleotide, sold widely as a longevity supplement. Its US regulatory status as a dietary supplement is contested after the FDA concluded it had been investigated as a drug.
Also known as: beta-nicotinamide mononucleotide, β-NMN
- Status
- Nicotinamide mononucleotide is a research compound and not approved by the FDA for human use.
- Evidence
- Human trials. Published clinical trials in people report results.
- Half-life
- Rapidly cleared from plasma; NAD+ metabolite elevation persists for hours.
- How it's taken
- Oral capsule or powder
- Mechanism
- Mitochondrial / longevity
- Pathways
- Mitochondrial, Nad Precursor
How Nicotinamide mononucleotide works
NAD+ is an essential cofactor for redox reactions and the substrate for sirtuins and PARPs, and its tissue levels decline with age. NMN is one step upstream of NAD+ in the salvage pathway: nicotinamide riboside is converted to NMN, and NMN is converted to NAD+ by NMNAT enzymes. Supplementing NMN reliably raises blood NAD+ metabolites; whether it raises NAD+ in the tissues that matter is a separate question.
What research has looked at
- Human trials consistently demonstrate that oral NMN raises blood NAD+ levels, so the biochemical premise is confirmed.
- Several small randomised trials report modest improvements in measures such as aerobic capacity in older adults and insulin sensitivity in prediabetic postmenopausal women.
- The decline of NAD+ with age is well documented, and its role in sirtuin and PARP function is established biochemistry.
- Short-term safety in trials has been good.
Evidence level: Human trials. Published clinical trials in people report results. These are areas studied or reported, not promised effects.
Reported side effects and risks
- The gap between raising blood NAD+ and producing a health outcome is where the evidence is thin. No trial has demonstrated an effect on ageing, lifespan, or hard clinical outcomes in humans. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- The FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug, leaving its legal status in the US unsettled.
- Whether oral NMN is absorbed intact or first degraded to nicotinamide riboside remains genuinely disputed in the literature.
- Theoretical concern exists that raising NAD+ could support the metabolism of existing malignancy, and this has not been resolved.
- Product purity varies substantially; independent testing has found products containing far less NMN than labelled.
Sources
- PubMed research on NMN NAD+ human trial regulatory status · NIH · National Library of Medicine
- DrugBank record for nicotinamide mononucleotide · DrugBank
- Active clinical trials for nicotinamide mononucleotide · U.S. National Library of Medicine
Track Nicotinamide mononucleotide in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Nicotinamide mononucleotide FAQ
What is Nicotinamide mononucleotide?
NMN is a nucleotide precursor to nicotinamide adenine dinucleotide, sold widely as a longevity supplement. Its US regulatory status as a dietary supplement is contested after the FDA concluded it had been investigated as a drug.
How does Nicotinamide mononucleotide work?
NAD+ is an essential cofactor for redox reactions and the substrate for sirtuins and PARPs, and its tissue levels decline with age. NMN is one step upstream of NAD+ in the salvage pathway: nicotinamide riboside is converted to NMN, and NMN is converted to NAD+ by NMNAT enzymes. Supplementing NMN reliably raises blood NAD+ metabolites; whether it raises NAD+ in the tissues that matter is a separate question.
Is Nicotinamide mononucleotide FDA approved?
No. Nicotinamide mononucleotide is a research compound and not approved by the FDA for human use. Evidence level: human trials. Published clinical trials in people report results.
What is the half-life of Nicotinamide mononucleotide?
Reported half-life: Rapidly cleared from plasma; NAD+ metabolite elevation persists for hours.
How is Nicotinamide mononucleotide taken?
Oral capsule or powder.
What side effects have been reported with Nicotinamide mononucleotide?
Reported in the sources: The gap between raising blood NAD+ and producing a health outcome is where the evidence is thin. No trial has demonstrated an effect on ageing, lifespan, or hard clinical outcomes in humans. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; The FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug, leaving its legal status in the US unsettled; Whether oral NMN is absorbed intact or first degraded to nicotinamide riboside remains genuinely disputed in the literature; Theoretical concern exists that raising NAD+ could support the metabolism of existing malignancy, and this has not been resolved; Product purity varies substantially; independent testing has found products containing far less NMN than labelled.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.